Novo Nordisk (NOVO) Fireside chat summary

Introduction and agenda

• The session focused on R&D and pipeline developments, with an emphasis on diabetes, obesity, and related comorbidities, and included a Q&A segment with the audience.

Background and experience of the speaker

• Martin Holst Lange discussed his new role and responsibilities, highlighting the recent re-merger of research and development functions to drive scientific and strategic synergies and improve decision-making speed.

Current industry trends

• Emphasis on the growing importance of obesity and diabetes treatments, with a focus on comorbidities such as cardiovascular and kidney diseases.

• Real-world evidence continues to confirm the cardiovascular benefits of semaglutide, distinguishing it in the obesity and diabetes space.

• The need for patient-centric approaches in clinical trial design, including flexible titration and consideration of individual patient needs, is increasingly recognized.